|
Volumn 4, Issue 2, 2002, Pages 59-63
|
Nevirapine resistance after single dose prophylaxis
a
|
Author keywords
HIV 1; Mother to child transmission; Nevirapine; Prophylaxis; Resistance
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CD4 ANTIGEN;
DELAVIRDINE;
EFAVIRENZ;
LAMIVUDINE;
NEVIRAPINE;
RNA DIRECTED DNA POLYMERASE;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
ZIDOVUDINE;
ANTIBIOTIC PROPHYLAXIS;
ANTIBIOTIC RESISTANCE;
BIRTH;
CLINICAL TRIAL;
CROSS RESISTANCE;
DOSE RESPONSE;
DRUG ABSORPTION;
DRUG CLEARANCE;
DRUG COST;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG EXPOSURE;
DRUG HALF LIFE;
DRUG POTENCY;
FEMALE;
HEALTH CARE PLANNING;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INFANT;
LABOR;
LYMPHOCYTE COUNT;
NONHUMAN;
RESOURCE MANAGEMENT;
REVIEW;
VERTICAL TRANSMISSION;
VIRUS DETECTION;
VIRUS LOAD;
VIRUS MUTATION;
CD4 LYMPHOCYTE COUNT;
DISEASE TRANSMISSION;
DRUG EFFECT;
GENETICS;
MUTATION;
PREGNANCY;
PREGNANCY COMPLICATION;
UGANDA;
CD4 LYMPHOCYTE COUNT;
DISEASE TRANSMISSION, VERTICAL;
DRUG RESISTANCE, VIRAL;
FEMALE;
HIV INFECTIONS;
HIV-1;
HUMAN;
INFANT;
MUTATION;
NEVIRAPINE;
PREGNANCY;
PREGNANCY COMPLICATIONS, INFECTIOUS;
REVERSE TRANSCRIPTASE INHIBITORS;
SUPPORT, U.S. GOV'T, P.H.S.;
UGANDA;
VIRAL LOAD;
HUMANS;
|
EID: 0035988448
PISSN: 11396121
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (64)
|
References (24)
|